Refine
Year of publication
Language
- English (144)
Has Fulltext
- yes (144)
Is part of the Bibliography
- no (144)
Keywords
- Heavy-ion collisions (4)
- Diffraction (3)
- Beam Energy Scan (2)
- Chiral Magnetic Effect (2)
- Collectivity (2)
- Correlation (2)
- Elastic scattering (2)
- Shear viscosity (2)
- B-slope (1)
- Beam energy scan (1)
- Charged-particle multiplicity (1)
- Charm quark spatial diffusion coefficient (1)
- Chiral magnetic effect (1)
- Coalescence (1)
- Cold nuclear matter effects (1)
- Critical point (1)
- DMARDs (biologic) (1)
- DMARDs (synthetic) (1)
- Deuteron production (1)
- Di-hadron correlations (1)
- Elliptic flow (1)
- Forward physics (1)
- Genetics (1)
- Groomed jet radius (1)
- Hadron-Hadron scattering (experiments) (1)
- Hadronization (1)
- Heavy Ion Experiments (1)
- Heavy Quark Production (1)
- Heavy ion collisions (1)
- Heavy-Ion Collision (1)
- Heavy-flavor decay electron (1)
- Higher moments (1)
- Interference fragmentation function (1)
- J/ψ suppression (1)
- Jet substructure (1)
- Molecular biology (1)
- Multiple parton interactions (1)
- Net-charge correlations (1)
- Net-charge fluctuations (1)
- Proton-proton collisions (1)
- Proton–proton collisions (1)
- Quarkonium (1)
- RHIC (1)
- STAR (1)
- SoftDrop (1)
- Splitting function (1)
- Thermal model (1)
- Transversity (1)
- heavy-ion collisions (1)
- methotrexate (1)
- p+p collisions (1)
- psoriatic arthritis (1)
- Υ suppression (1)
Institute
- Frankfurt Institute for Advanced Studies (FIAS) (99)
- Physik (42)
- Medizin (2)
Data from the first physics run at the Relativistic Heavy-Ion Collider at Brookhaven National Laboratory, Au+Au collisions at sqrt[sNN]=130 GeV, have been analyzed by the STAR Collaboration using three-pion correlations with charged pions to study whether pions are emitted independently at freeze-out. We have made a high-statistics measurement of the three-pion correlation function and calculated the normalized three-particle correlator to obtain a quantitative measurement of the degree of chaoticity of the pion source. It is found that the degree of chaoticity seems to increase with increasing particle multiplicity.
We present the first measurements of charge-dependent correlations on angular difference variables η1 − η2 (pseudorapidity) and φ1 − φ2 (azimuth) for primary charged hadrons with transverse momentum 0.15 <= pt <= 2 GeV/c and |η| <= 1.3 from Au–Au collisions at √sNN = 130 GeV. We observe correlation structures not predicted by theory but consistent with evolution of hadron emission geometry with increasing centrality from one-dimensional fragmentation of color strings along the beam direction to an at least two-dimensional hadronization geometry along the beam and azimuth directions of a hadron-opaque bulk medium.
DNA methylation profiles of aggressive behavior may capture lifetime cumulative effects of genetic, stochastic, and environmental influences associated with aggression. Here, we report the first large meta-analysis of epigenome-wide association studies (EWAS) of aggressive behavior (N = 15,324 participants). In peripheral blood samples of 14,434 participants from 18 cohorts with mean ages ranging from 7 to 68 years, 13 methylation sites were significantly associated with aggression (alpha = 1.2 × 10−7; Bonferroni correction). In cord blood samples of 2425 children from five cohorts with aggression assessed at mean ages ranging from 4 to 7 years, 83% of these sites showed the same direction of association with childhood aggression (r = 0.74, p = 0.006) but no epigenome-wide significant sites were found. Top-sites (48 at a false discovery rate of 5% in the peripheral blood meta-analysis or in a combined meta-analysis of peripheral blood and cord blood) have been associated with chemical exposures, smoking, cognition, metabolic traits, and genetic variation (mQTLs). Three genes whose expression levels were associated with top-sites were previously linked to schizophrenia and general risk tolerance. At six CpGs, DNA methylation variation in blood mirrors variation in the brain. On average 44% (range = 3–82%) of the aggression–methylation association was explained by current and former smoking and BMI. These findings point at loci that are sensitive to chemical exposures with potential implications for neuronal functions. We hope these results to be a starting point for studies leading to applications as peripheral biomarkers and to reveal causal relationships with aggression and related traits.
Objective: To conduct subset analyses of SPIRIT-P2 (Standard Protocol Items: Recommendations for Interventional Trials, NCT02349295) to investigate the efficacy and safety of ixekizumab versus placebo in three subgroups of patients with active psoriatic arthritis (PsA) according to the concomitant conventional synthetic disease-modifying antirheumatic drug (cDMARD) received: any background cDMARDs (including methotrexate), background methotrexate only
Methods: Patients were randomised to receive placebo, ixekizumab 80 mg every 4 weeks (IXEQ4W) or every 2 weeks (IXEQ2W). Efficacy and safety were assessed when patients were subdivided according to cDMARD use at baseline. Efficacy was evaluated versus placebo at week 24 by the American College of Rheumatology criteria (ACR20/50), achievement of minimal disease activity (MDA) state, DiseaseActivityIndex for PsA (DAPSA), 28-joint DiseaseActivityScore using C reactive protein (DAS28-CRP), HealthAssessmentQuestionnaire-Disability Index and the 36-item Short-Form health survey physical functioning domain.
Results: Regardless of background cDMARD status, ACR20, ACR50 and MDA response rates were significantly higher than placebo with IXEQ4W or IXEQ2W treatment. Similarly, significant improvements were observed relative to placebo for DAS28-CRP and DAPSA across subgroups. Physical function also significantly improved relative to placebo with IXEQ4W treatment regardless of background cDMARD status and with IXEQ2W alone. Percentages of reported treatment emergent adverse events (AEs), serious AEs (including serious infections) and discontinuations due to AEs in each subgroup were comparable to the overall SPIRIT-P2 population.
Conclusion: Ixekizumab was efficacious in patients with active PsA and previous tumour necrosis factor inhibitor (TNFi)inadequate response or TNFi intolerance treated with ixekizumab alone or when added to cDMARDswith subgroup safety profiles that were consistent with that observed in the overall SPIRIT-P2 population.